title: Follow-up study of children with precocious puberty treated with cyproterone acetate. Ad hoc Committee for CPA.
abstract: A total of 1840 children and adolescents treated with cyproterone acetate (CPA) to block gonadal function, as a treatment for precocious puberty, short stature and other disorders, were registered to survey for the risk of developing hepatic tumors. Patients responding to follow-up numbered 1552 (85%). The cumulative dose and duration of CPA therapy for boys and girls were 110.4g and 2.6 years, and 122.9 g and 2.8 years, respectively. Among the 1552 patients, five hepatoma cases were found. Four underwent successful surgery and remain alive and well to date. Two of the 5 cases had been given more than 500g, the other 3 more than 1000 g, of CPA. Three had also been given androgens before CPA administration. Although further follow-up is necessary to monitor for the development of adenoma and hepatoma, the risk of developing these tumors among patients to whom limited doses of CPA were administered appears to be negligible.
authors.affiliation: Department of Nutrition and Epidemiology, Tokyo University of Agriculture, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Cui
authors.forename: A
authors.initials: A
authors.lastname: Tanae
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuo
authors.forename: K
authors.initials: K
authors.lastname: Tachibana
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
mesh_terms: D018248:Adenoma, Liver Cell / Q000139:chemically induced; D000293:Adolescent; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D017373:Cyproterone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D011629:Puberty, Precocious / Q000188:drug therapy*; D012306:Risk
chemical_list: D000726:Androgen Antagonists; D045167:Progesterone Congeners; D017373:Cyproterone Acetate